Newron Receives Fifth Tranche From Financing Agreement With European Investment Bank (Eib)

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe. Tranche 5 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system